Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304)

Tanaka, Kazuhiro; Mizusawa, Junki; Fukuda, Haruhiko; Araki, Nobuhito; Chuman, Hirokazu; Takahashi, Mitsuru; Ozaki, Toshifumi; Hiruma, Toru; Tsuchiya, Hiroyuki; Morioka, Hideo; Hatano, Hiroshi; Iwamoto, Yukihide

doi:10.1093/jjco/hyv042

Cited by 39 publications

(49 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choices of drug combinations and applications are continuously expanding. Recently, Dox has been combined with ifosfamide and tested in a Phase II study for the treatment of soft tissue sarcomas [17]. Albumin-bound PTX particles (Abraxane®) and gemcitabine (Gem) combination were approved by the US FDA as the first-line treatment for patients with metastatic pancreatic cancer [18].…”

Section: Clinically Used Combination Chemotherapymentioning

confidence: 99%

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy

Meng¹,

Han²,

Yeo³

2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction Chemotherapeutic drugs are used in combination to target multiple mechanisms involved in cancer cell survival and proliferation. Carriers are developed to deliver drug combinations to common target tissues in optimal ratios and desirable sequences. Nanoparticles (NP) have been a popular choice for this purpose due to their ability to increase the circulation half-life and tumor accumulation of a drug. Areas covered We review organic NP carriers based on polymers, proteins, peptides, and lipids for simultaneous delivery of multiple anticancer drugs, drug/sensitizer combinations, drug/photodynamic- or photothermal therapy combinations, and drug/gene therapeutics with examples in the past three years. Sequential delivery of drug combinations, based on either sequential administration or built-in release control, is introduced with an emphasis on the mechanistic understanding of such control. Expert opinion Recent studies demonstrate how a drug carrier can contribute to co-localizing drug combinations in optimal ratios and dosing sequences to maximize the synergistic effects. We identify several areas for improvement in future research, including the choice of drug combinations, circulation stability of carriers, spatiotemporal control of drug release, and the evaluation and clinical translation of combination delivery.

show abstract

Section: Clinically Used Combination Chemotherapymentioning

confidence: 99%

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy

Meng¹,

Han²,

Yeo³

2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…The most common agents are methotrexate, cyclophosphamide, and bleomycin (2)(3)(4). Ifosfamide is one of the standard drugs for soft tissue sarcomas (5,6). However, interstitial pneumonitis that is clearly associated with only ifosfamide, as in our case, has not been reported, although there have been some studies on interstitial pneumonitis after administration of combined chemotherapy including ifosfamide, which is used for bone and soft tissue sarcoma, and lymphoma (3,(7)(8)(9).…”

Section: Discussionmentioning

confidence: 63%

Radiation recall pneumonitis induced by ifosfamide for malignant soft tissue tumor arising from the chest wall: A case report

et al. 2018

View full text Add to dashboard Cite

Abstract. The present study reports a rare case of radiation recall pneumonitis attributed to ifosfamide that was used as a single antitumor agent for a recurrent malignant soft tissue tumor, arising from the chest wall. A 74-year-old man, who had a mass in his right upper chest wall, underwent surgical excision under the diagnosis of chronic expanding hematoma. He was referred to the present hospital with a recurrent tumor as the excised tumor was diagnosed as undifferentiated high-grade sarcoma. The extension of the tumor following previous surgery was aggressive and the tumor margins were unclear on magnetic resonance imaging. Wide excision was done with adequate margins for the new recurrent tumor as it was difficult to set sufficient tumor margins following the previous surgery. Radiotherapy (60 Gy) on his right subclavicular area and chemotherapy with ifosfamide (3.5 g x 4 days/cycle) was started 1 month following surgery to control the growth of residual tumors and to prevent metastases. The third cycle of chemotherapy with ifosfamide (3 g x 4 days) was started 80 days following the final surgery and 15 days following termination of radiotherapy. Following administration, he felt short of breath and dyspnea gradually increased. This condition was diagnosed as interstitial pneumonitis induced by ifosfamide following radiotherapy. Although corticosteroid pulse therapy was performed, he died due to respiratory failure. To the best of the author's knowledge, this is the first case report of radiation recall pneumonitis induced by ifosfamide used as a single anti-tumor agent. Caution is needed when ifosfamide is planned for patients who have undergone previous radiotherapy to the chest.

show abstract

“…e results of the study by Tanaka et al support the use of preoperative chemotherapy followed by postoperative chemotherapy consisting of three cycles of doxorubicin 60 mg/m 2 and ifosfamide 10 g/m 2 for localized high-risk extremity or trunk wall STS [13]. In this regard both, the noninferiority of three cycles of a full-dose conventional chemotherapy (epirubicin and ifosfamide) in comparison with five cycles and the association between response to therapy and better rates of overall survival (OS), particularly when Choi criteria are used for the evaluation, have been pinpointed in a randomized trial [11].…”

Section: Localized High-risk Stsmentioning

confidence: 90%

Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus

Álvarez

Jurado

Soláns

et al. 2019

Sarcoma

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) constitute a heterogeneous group of rare solid tumors associated with significant morbidity and mortality. The evaluation and treatment of STS require a multidisciplinary team with extensive experience in the management of these types of tumors. National and international clinical practice guidelines for STS do not always provide answers to a great many situations that specialists have to contend with in their everyday practice. This consensus provides a series of specific recommendations based on available scientific evidence and the experience of a group of experts to assist in decision-making by all the specialists involved in the management of STS.

show abstract

Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304)

Cited by 39 publications

References 13 publications

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy

Radiation recall pneumonitis induced by ifosfamide for malignant soft tissue tumor arising from the chest wall: A case report

Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus

Contact Info

Product

Resources

About